Cargando…
Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease
Diabetic kidney disease (DKD) is the main complication in diabetes mellitus (DM) and the main cause of end-stage kidney disease worldwide. However, sodium glucose cotransporter 2 (SGLT2) inhibition, glucagon-like peptide-1 (GLP-1) receptor agonist, mineralocorticoid receptor antagonists and endothel...
Autores principales: | Chen, Xian, Dai, Wenni, Li, Hao, Yan, Zhe, Liu, Zhiwen, He, Liyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809356/ https://www.ncbi.nlm.nih.gov/pubmed/36576203 http://dx.doi.org/10.1080/10717544.2022.2160518 |
Ejemplares similares
-
Renal Proximal Tubular Cells: A New Site for Targeted Delivery Therapy of Diabetic Kidney Disease
por: Li, Hao, et al.
Publicado: (2022) -
Biopolymer-Based Nanosystems: Potential Novel Carriers for Kidney Drug Delivery
por: Li, Hao, et al.
Publicado: (2023) -
The Loss of Mitochondrial Quality Control in Diabetic Kidney Disease
por: Dai, Wenni, et al.
Publicado: (2021) -
RvD1 Attenuated Susceptibility to Ischemic AKI in Diabetes by Downregulating Nuclear Factor-κ B Signal and Inhibiting Apoptosis
por: Li, Zheng, et al.
Publicado: (2021) -
Targeting Renal Proximal Tubule Cells in Obesity-Related Glomerulopathy
por: Ye, Muyao, et al.
Publicado: (2023)